Covered recipient · General Payments record
KEVIN D CANNON
Allopathic & Osteopathic Physicians Hospitalist
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$58.19
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $32.27 | 1 |
| Food and Beverage | $25.92 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk Inc | $32.27 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.92 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KEVIN D CANNON
NPI 1700897022 · CMS profile ID 122867
Allopathic & Osteopathic Physicians / Hospitalist
WILMINGTON, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $58.19 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.92 | 08/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887506015 | CMS |
| Novo Nordisk Inc | $32.27 | 06/08/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898661569 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,200.00 | 1 |
| PY2025 | Principal investigator | $6,407,903.58 | 738 |
| PY2024 | Recipient | $12,299.41 | 13 |
| PY2024 | Principal investigator | $7,058,469.69 | 390 |
| PY2023 | Recipient | $3,980.00 | 2 |
| PY2023 | Principal investigator | $7,125,617.33 | 899 |
| PY2022 | Recipient | $9,082.00 | 12 |
| PY2022 | Principal investigator | $6,929,547.49 | 979 |
| PY2021 | Recipient | $14,312.20 | 61 |
| PY2021 | Principal investigator | $9,361,495.59 | 2,459 |
| PY2020 | Recipient | $233.41 | 1 |
| PY2020 | Principal investigator | $5,812,787.31 | 750 |
| PY2019 | Principal investigator | $4,820,055.08 | 826 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
2,520 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $12,096.04 | 12/31/2021 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | No dispute reported | 06/30/2026 | 848761455 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 12/31/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 833635509 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 12/31/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 833635535 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 12/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428099 |
| Principal investigator 1 | Novo Nordisk AS | $5,832.58 | 12/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879373 |
| Principal investigator 1 | Novo Nordisk AS | $4,511.32 | 12/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901413 |
| Principal investigator 1 | PFIZER INC. | $413.83 | 12/29/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832563973 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $6,462.00 | 12/28/2021 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787568489 |
| Principal investigator 1 | PFIZER INC. | $2,345.38 | 12/28/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832563259 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 12/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711627 |
| Principal investigator 1 | PFIZER INC. | $1,655.32 | 12/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832558099 |
| Principal investigator 1 | PFIZER INC. | $7,819.20 | 12/24/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | No dispute reported | 06/30/2026 | 832558949 |
| Principal investigator 1 | Novo Nordisk AS | $2,804.34 | 12/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829755 |
| Principal investigator 1 | PFIZER INC. | $2,926.80 | 12/23/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832563239 |
| Principal investigator 1 | Novo Nordisk AS | $9,688.31 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299307 |
| Principal investigator 1 | Novo Nordisk AS | $4,468.78 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325203 |
| Principal investigator 1 | Novo Nordisk AS | $8,430.09 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537141 |
| Principal investigator 1 | Novo Nordisk AS | $5,155.36 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603247 |
| Principal investigator 1 | Novo Nordisk AS | $7,930.17 | 12/22/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780887 |
| Principal investigator 1 | Novo Nordisk AS | $78,289.40 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811791543 |
| Principal investigator 1 | Novo Nordisk AS | $2,638.12 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808739 |
| Principal investigator 1 | Novo Nordisk AS | $2,861.90 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863147 |
| Principal investigator 1 | Novo Nordisk AS | $2,565.00 | 12/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886443 |
| Principal investigator 1 | PFIZER INC. | $10,916.64 | 12/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832523901 |
| Principal investigator 1 | PFIZER INC. | $12,963.51 | 12/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832523913 |
| Principal investigator 1 | PFIZER INC. | $37,339.65 | 12/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832558589 |
| Principal investigator 1 | PFIZER INC. | $2,581.95 | 12/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162B2 IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832563249 |
| Principal investigator 1 | PFIZER INC. | $28,178.55 | 12/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 832563649 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 12/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810791503 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 12/17/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428081 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 12/17/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428088 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $345.98 | 12/16/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023577 |
| Recipient | Novo Nordisk AS | $6.00 | 12/16/2021 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 811721641 |
| Recipient | Novo Nordisk AS | $240.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811721665 |
| Recipient | Novo Nordisk AS | $240.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811721671 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735719 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735725 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735731 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735837 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735843 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735849 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735937 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736255 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736261 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736267 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736273 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736279 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736285 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736291 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736297 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736301 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736307 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811740243 |
| Principal investigator 1 | Novo Nordisk AS | $299.80 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811791539 |
| Principal investigator 1 | Novo Nordisk AS | $299.80 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811791541 |
| Recipient | Novo Nordisk AS | $6.00 | 12/16/2021 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 811797143 |
| Recipient | Novo Nordisk AS | $220.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4635 | No dispute reported | 06/30/2026 | 811797157 |
| Recipient | Novo Nordisk AS | $270.00 | 12/16/2021 | Covered Recipient Physician | NN1436-4478 | No dispute reported | 06/30/2026 | 811797163 |
| Recipient | Novo Nordisk AS | $6.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811797167 |
| Recipient | Novo Nordisk AS | $240.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811797171 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800013 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800015 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800017 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800019 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800021 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800023 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800025 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800027 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800061 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800063 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800065 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800067 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800069 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800071 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800073 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800075 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800077 |
| Principal investigator 1 | Novo Nordisk AS | $299.80 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811880373 |
| Recipient | Novo Nordisk AS | $270.00 | 12/16/2021 | Covered Recipient Physician | NN1436-4479 | No dispute reported | 06/30/2026 | 811884513 |
| Recipient | Novo Nordisk AS | $6.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884515 |
| Recipient | Novo Nordisk AS | $240.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884517 |
| Recipient | Novo Nordisk AS | $200.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884519 |
| Recipient | Novo Nordisk AS | $240.00 | 12/16/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884521 |
| Recipient | Novo Nordisk AS | $240.00 | 12/16/2021 | Covered Recipient Physician | NN1436-4477 | No dispute reported | 06/30/2026 | 811884533 |
| Recipient | Novo Nordisk AS | $240.00 | 12/16/2021 | Covered Recipient Physician | NN1436-4477 | No dispute reported | 06/30/2026 | 811884535 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886431 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886433 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886435 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886437 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886439 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886523 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886525 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886527 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886529 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886531 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886533 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886535 |
| Principal investigator 1 | Novo Nordisk AS | $299.80 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811901297 |
| Principal investigator 1 | Novo Nordisk AS | $299.80 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811901307 |
| Recipient | Novo Nordisk AS | $270.00 | 12/16/2021 | Covered Recipient Physician | NN1436-4478 | No dispute reported | 06/30/2026 | 811904113 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905401 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905403 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905405 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905407 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905409 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905411 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905441 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905443 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905445 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905447 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905449 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905451 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905453 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905455 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905457 |
| Principal investigator 1 | Novo Nordisk AS | $74.85 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905459 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905461 |
| Principal investigator 1 | Novo Nordisk AS | $32.50 | 12/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905463 |
| Principal investigator 1 | Novo Nordisk AS | $78.84 | 12/15/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871395 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 12/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811691113 |
| Principal investigator 1 | Novo Nordisk AS | $609.00 | 12/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735855 |
| Principal investigator 1 | Novo Nordisk AS | $1,270.00 | 12/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800029 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 12/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886441 |
| Principal investigator 1 | PFIZER INC. | $38,871.36 | 12/10/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832523893 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127943 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127957 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128545 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128555 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128689 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128701 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128935 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128949 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128963 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128977 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128989 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811129003 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811129015 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465265 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465275 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465285 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465295 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465305 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465315 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465325 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465331 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465341 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465571 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465581 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465591 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465601 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465611 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465621 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465743 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465783 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465791 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465799 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465809 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465819 |
| Recipient | Novo Nordisk AS | $200.00 | 12/09/2021 | Covered Recipient Physician | NN9838-4862 | No dispute reported | 06/30/2026 | 811721647 |
| Recipient | Novo Nordisk AS | $220.00 | 12/09/2021 | Covered Recipient Physician | NN1436-4478 | No dispute reported | 06/30/2026 | 811721653 |
| Recipient | Novo Nordisk AS | $200.00 | 12/09/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811721659 |
| Recipient | Novo Nordisk AS | $270.00 | 12/09/2021 | Covered Recipient Physician | NN9838-4862 | No dispute reported | 06/30/2026 | 811797149 |
| Recipient | Novo Nordisk AS | $220.00 | 12/09/2021 | Covered Recipient Physician | NN9838-4862 | No dispute reported | 06/30/2026 | 811797151 |
| Recipient | Novo Nordisk AS | $200.00 | 12/09/2021 | Covered Recipient Physician | NN1436-4479 | No dispute reported | 06/30/2026 | 811797165 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808401 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808403 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808405 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808407 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808607 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808609 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808611 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808613 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808615 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808617 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808619 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808621 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808623 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808685 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808687 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808733 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808735 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808737 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808741 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808743 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808745 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808747 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808749 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842035 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842037 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842039 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842057 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842059 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842119 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842121 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842123 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842133 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842135 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842137 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842139 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842141 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842143 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842183 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842185 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811843213 |
| Recipient | Novo Nordisk AS | $200.00 | 12/09/2021 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 811904105 |
| Recipient | Novo Nordisk AS | $220.00 | 12/09/2021 | Covered Recipient Physician | NN9838-4862 | No dispute reported | 06/30/2026 | 811904109 |
| Recipient | Novo Nordisk AS | $220.00 | 12/09/2021 | Covered Recipient Physician | NN1436-4479 | No dispute reported | 06/30/2026 | 811904117 |
| Recipient | Novo Nordisk AS | $240.00 | 12/09/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811904121 |
| Principal investigator 1 | Novo Nordisk AS | $143.55 | 12/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905439 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 12/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299327 |
| Principal investigator 1 | Novo Nordisk AS | $24.56 | 12/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867891 |
| Principal investigator 1 | PFIZER INC. | $1,893.43 | 12/08/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162B2 IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832558943 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 12/07/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711617 |
| Principal investigator 1 | PFIZER INC. | $413.83 | 12/07/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832558583 |
| Principal investigator 1 | PFIZER INC. | $18,064.35 | 12/07/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 832558933 |
| Principal investigator 1 | PFIZER INC. | $743.85 | 12/07/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832563957 |
| Principal investigator 1 | PFIZER INC. | $6,480.00 | 12/07/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832563965 |
| Principal investigator 1 | Novo Nordisk AS | $26.00 | 12/06/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894295 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721065 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721072 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721081 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721091 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721101 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721111 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721121 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721129 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721185 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721193 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721203 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721213 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721223 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721233 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721241 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721252 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810798949 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810798960 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810798969 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810798979 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799035 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799045 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799055 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799065 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799073 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799083 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799093 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799103 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799113 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799161 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799171 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799181 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799191 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799201 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799211 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799221 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799231 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810801887 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810801897 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810801907 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811321997 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322349 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322357 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322365 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322373 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322381 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322391 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322401 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322411 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322421 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322429 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322437 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325117 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325123 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325134 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325143 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325153 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325163 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325173 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325183 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325193 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811331357 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469045 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469051 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469061 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469123 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469131 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469139 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469149 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469285 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469291 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469301 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469311 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469321 |
| Principal investigator 1 | Novo Nordisk AS | $39.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469361 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469371 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469379 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811480665 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811880369 |
| Principal investigator 1 | Novo Nordisk AS | $609.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811901299 |
| Principal investigator 1 | Novo Nordisk AS | $1,270.00 | 12/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811901301 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242019 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242027 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242055 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242101 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242111 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242453 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242461 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242471 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536853 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536863 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536873 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536883 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536889 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536899 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536909 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536919 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536945 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536955 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536965 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536975 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536985 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811537005 |
| Recipient | Novo Nordisk AS | $270.00 | 12/02/2021 | Covered Recipient Physician | NN9924-4635 | No dispute reported | 06/30/2026 | 811797153 |
| Recipient | Novo Nordisk AS | $270.00 | 12/02/2021 | Covered Recipient Physician | NN9924-4635 | No dispute reported | 06/30/2026 | 811797155 |
| Recipient | Novo Nordisk AS | $270.00 | 12/02/2021 | Covered Recipient Physician | NN1436-4478 | No dispute reported | 06/30/2026 | 811797161 |
| Recipient | Novo Nordisk AS | $200.00 | 12/02/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811797169 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833879 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833881 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833883 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833885 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833889 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857811 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857813 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857823 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857829 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857831 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857833 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857835 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857837 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857839 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857841 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857843 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857845 |
| Principal investigator 1 | Novo Nordisk AS | $22.86 | 12/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900921 |
| Recipient | Novo Nordisk AS | $200.00 | 12/02/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811904119 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023565 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $90.65 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023567 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023581 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023583 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $77.46 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023757 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $90.65 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023759 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023761 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023765 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023767 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023769 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023771 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023773 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023775 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023777 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023779 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023781 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023783 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023785 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023787 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.31 | 12/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023789 |
| Principal investigator 1 | Novo Nordisk AS | $875.20 | 12/01/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833893 |
| Principal investigator 1 | Novo Nordisk AS | $14,117.66 | 12/01/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871399 |
| Principal investigator 1 | Novo Nordisk AS | $8,387.07 | 12/01/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890905 |
| Principal investigator 1 | Novo Nordisk AS | $2,560.79 | 12/01/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900847 |
| Principal investigator 1 | PFIZER INC. | $1,456.76 | 12/01/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832558107 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 11/30/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 833635513 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 11/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 833635539 |
| Principal investigator 1 | PFIZER INC. | $743.85 | 11/30/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832828697 |
| Principal investigator 1 | PFIZER INC. | $743.85 | 11/30/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832904191 |
| Principal investigator 1 | Novo Nordisk AS | $10,084.27 | 11/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811010557 |
| Principal investigator 1 | Novo Nordisk AS | $7,473.55 | 11/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595987 |
| Principal investigator 1 | Novo Nordisk AS | $297.00 | 11/28/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 833635505 |
| Principal investigator 1 | Novo Nordisk AS | $297.00 | 11/28/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 833635507 |
| Principal investigator 1 | Novo Nordisk AS | $297.00 | 11/28/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 833635515 |
| Principal investigator 1 | Novo Nordisk AS | $297.00 | 11/28/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 833635517 |
| Principal investigator 1 | Novo Nordisk AS | $6,458.78 | 11/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469071 |
| Recipient | Novo Nordisk AS | $200.00 | 11/24/2021 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 811797145 |
| Recipient | Novo Nordisk AS | $175.00 | 11/24/2021 | Covered Recipient Physician | NN9924-4635 | No dispute reported | 06/30/2026 | 811797159 |
| Recipient | Novo Nordisk AS | $240.00 | 11/24/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811797175 |
| Principal investigator 1 | Novo Nordisk AS | $4,435.02 | 11/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798763 |
| Recipient | Novo Nordisk AS | $240.00 | 11/24/2021 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 811884507 |
| Recipient | Novo Nordisk AS | $75.00 | 11/24/2021 | Covered Recipient Physician | NN9535-4321 | No dispute reported | 06/30/2026 | 811884509 |
| Recipient | Novo Nordisk AS | $175.00 | 11/24/2021 | Covered Recipient Physician | NN9924-4635 | No dispute reported | 06/30/2026 | 811884511 |
| Recipient | Novo Nordisk AS | $270.00 | 11/24/2021 | Covered Recipient Physician | NN1436-4477 | No dispute reported | 06/30/2026 | 811884537 |
| Recipient | Novo Nordisk AS | $125.00 | 11/24/2021 | Covered Recipient Physician | NN1436-4477 | No dispute reported | 06/30/2026 | 811884539 |
| Recipient | Novo Nordisk AS | $240.00 | 11/24/2021 | Covered Recipient Physician | NN9924-4635 | No dispute reported | 06/30/2026 | 811904111 |
| Recipient | Novo Nordisk AS | $240.00 | 11/24/2021 | Covered Recipient Physician | NN1436-4478 | No dispute reported | 06/30/2026 | 811904115 |
| Recipient | Novo Nordisk AS | $220.00 | 11/24/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811904125 |
| Principal investigator 1 | PFIZER INC. | $172.13 | 11/24/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162B2 IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832624591 |
| Principal investigator 1 | PFIZER INC. | $1,969.87 | 11/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832691765 |
| Principal investigator 1 | PFIZER INC. | $24,590.25 | 11/23/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 832617549 |
| Principal investigator 1 | PFIZER INC. | $162,055.35 | 11/23/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832617569 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 11/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711580 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 11/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413013 |
| Principal investigator 1 | PFIZER INC. | $22,511.36 | 11/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832518459 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811721677 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811721683 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811797173 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811797177 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9536-4578 | No dispute reported | 06/30/2026 | 811797251 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884523 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884525 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884527 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884529 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811884531 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9536-4578 | No dispute reported | 06/30/2026 | 811884545 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9536-4578 | No dispute reported | 06/30/2026 | 811884547 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811904123 |
| Recipient | Novo Nordisk AS | $6.00 | 11/18/2021 | Covered Recipient Physician | NN9924-4473 | No dispute reported | 06/30/2026 | 811904127 |
| Recipient | Novo Nordisk AS | $12.00 | 11/18/2021 | Covered Recipient Physician | NN9536-4578 | No dispute reported | 06/30/2026 | 811904129 |
| Principal investigator 1 | PFIZER INC. | $1,181.56 | 11/18/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832700129 |
| Principal investigator 1 | PFIZER INC. | $2,673.00 | 11/16/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832604635 |
| Principal investigator 1 | PFIZER INC. | $2,231.55 | 11/16/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832804053 |
| Principal investigator 1 | PFIZER INC. | $3,441.69 | 11/16/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832845641 |
| Principal investigator 1 | Novo Nordisk AS | $50.12 | 11/12/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413003 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 11/12/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428021 |
| Principal investigator 1 | Novo Nordisk AS | $49.75 | 11/12/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811901305 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,325.12 | 11/11/2021 | Non-covered Recipient Entity PMG RESEARCH LLC | Not supplied | No dispute reported | 06/30/2026 | 809515441 |
| Principal investigator 1 | Novo Nordisk AS | $1,485.00 | 11/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 833635527 |
| Principal investigator 1 | Novo Nordisk AS | $594.00 | 11/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 833635529 |
| Principal investigator 1 | Novo Nordisk AS | $1,485.00 | 11/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 833635531 |
| Principal investigator 1 | Novo Nordisk AS | $594.00 | 11/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 833635533 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299281 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735629 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735635 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735641 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735647 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735653 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735659 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735665 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735671 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735677 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735683 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735689 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735877 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735883 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735889 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735895 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735901 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735907 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735914 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736349 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736355 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799983 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799985 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799987 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799989 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799991 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799993 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799995 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799997 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799999 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800035 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800037 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800039 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800041 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800043 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800045 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800047 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800049 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800087 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886303 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886409 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886411 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886413 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886415 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886417 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886419 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886421 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886423 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886493 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886495 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886497 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886499 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886501 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886503 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886505 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886507 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886509 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886545 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886547 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886549 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886551 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905373 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905375 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905377 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905379 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905381 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905383 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905385 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905387 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905389 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905423 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905425 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905427 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905429 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905431 |
| Principal investigator 1 | Novo Nordisk AS | $11.40 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905475 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905477 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905479 |
| Principal investigator 1 | PFIZER INC. | $5,300.64 | 11/10/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832517605 |
| Principal investigator 1 | PFIZER INC. | $827.66 | 11/10/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832774941 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735695 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735701 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735707 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735713 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735919 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735925 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735931 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736781 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800001 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800003 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800005 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800007 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800009 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800011 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800051 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800053 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800055 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800057 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800059 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800413 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886425 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886427 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886429 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886511 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886513 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886515 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886517 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886519 |
| Principal investigator 1 | Novo Nordisk AS | $1.97 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886521 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886553 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886555 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905391 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905393 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905395 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905397 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905399 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905433 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905435 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905437 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905481 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905483 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905485 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905487 |
| Principal investigator 1 | PFIZER INC. | $2,697.84 | 11/09/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832702527 |
| Principal investigator 1 | PFIZER INC. | $20,504.61 | 11/09/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832727059 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758353 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758359 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758365 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758370 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758375 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758381 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758387 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758393 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758399 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758405 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758411 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758417 |
| Principal investigator 1 | Novo Nordisk AS | $8.00 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758423 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758429 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758435 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758439 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758445 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811758545 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791811 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801955 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801957 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801959 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801961 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801963 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801965 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801967 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801969 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801971 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801973 |
| Principal investigator 1 | Novo Nordisk AS | $5.70 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801975 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801977 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801979 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801981 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811801983 |
| Principal investigator 1 | Novo Nordisk AS | $25.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879507 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880671 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895325 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895327 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895329 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895331 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895333 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895335 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895337 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895339 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895341 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895343 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895345 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895347 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895349 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895351 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895353 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895355 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895357 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895359 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895361 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895363 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895365 |
| Principal investigator 1 | Novo Nordisk AS | $22.80 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895367 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895405 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895407 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811895409 |
| Principal investigator 1 | Novo Nordisk AS | $25.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900919 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907333 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907335 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907337 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907339 |
| Principal investigator 1 | Novo Nordisk AS | $2.96 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907341 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907343 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907345 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907347 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907349 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907351 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907353 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907355 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907357 |
| Principal investigator 1 | Novo Nordisk AS | $39.90 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907359 |
| Principal investigator 1 | Novo Nordisk AS | $9.74 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907361 |
| Principal investigator 1 | Novo Nordisk AS | $40.00 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907363 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907365 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907367 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 11/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1535-4593 | No dispute reported | 06/30/2026 | 811907369 |
| Principal investigator 1 | PFIZER INC. | $670.95 | 11/05/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600945 |
| Principal investigator 1 | PFIZER INC. | $10,682.55 | 11/05/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 832616945 |
| Principal investigator 1 | PFIZER INC. | $1,450.00 | 11/05/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832695737 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292787 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292795 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292805 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595273 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595283 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837257 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837259 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863017 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 11/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863359 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686285 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686289 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686295 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686301 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686307 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686313 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686317 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686323 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686329 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686335 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686793 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686799 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686811 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686817 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686823 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686829 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687169 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687491 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687497 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790111 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790113 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790187 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790189 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790191 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790193 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790195 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790197 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790223 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790225 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790227 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790229 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790231 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790233 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790235 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790239 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790241 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790243 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790245 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790247 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790249 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790251 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790253 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790399 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790401 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790403 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790443 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790445 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790447 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879219 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879221 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879223 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879225 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879227 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879229 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879231 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879233 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879235 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879237 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879291 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879293 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879295 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879301 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879303 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879305 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879307 |
| Principal investigator 1 | Novo Nordisk AS | $46.35 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879309 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879311 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879313 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879315 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879317 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879319 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879321 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879323 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879361 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879363 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879365 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879367 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879369 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879371 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879439 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879441 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879463 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879465 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879467 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879469 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900769 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900771 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900773 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900775 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900777 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900779 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900781 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900783 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900785 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900787 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900789 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900791 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900793 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900795 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900797 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900817 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900819 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900827 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900829 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900831 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900833 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900835 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900837 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900839 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900841 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900843 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900845 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900893 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900895 |
| Principal investigator 1 | Novo Nordisk AS | $17.10 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900913 |
| Principal investigator 1 | Novo Nordisk AS | $22.76 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900915 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 11/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900917 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023573 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023605 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023607 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $92.46 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023619 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $79.00 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023621 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023629 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023631 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023633 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023635 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023637 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023639 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023641 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023643 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023645 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023647 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023649 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023651 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023653 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $33.98 | 11/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023655 |
| Principal investigator 1 | PFIZER INC. | $3,328.38 | 10/30/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832822027 |
| Principal investigator 1 | Novo Nordisk AS | $3,442.52 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322305 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693189 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790385 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791805 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791807 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791809 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900887 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900889 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900911 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 10/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 833635511 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 10/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 833635537 |
| Principal investigator 1 | PFIZER INC. | $270.00 | 10/29/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832616935 |
| Principal investigator 1 | PFIZER INC. | $51,444.45 | 10/29/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832691323 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 10/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900891 |
| Principal investigator 1 | Novo Nordisk AS | $3,377.82 | 10/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099089 |
| Principal investigator 1 | Novo Nordisk AS | $875.20 | 10/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242071 |
| Principal investigator 1 | Novo Nordisk AS | $1,116.85 | 10/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299301 |
| Principal investigator 1 | Novo Nordisk AS | $187.50 | 10/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536995 |
| Principal investigator 1 | Novo Nordisk AS | $3,489.48 | 10/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650665 |
| Principal investigator 1 | Novo Nordisk AS | $1,765.83 | 10/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837323 |
| Principal investigator 1 | PFIZER INC. | $4,709.53 | 10/27/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832866069 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $1,773.73 | 10/26/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023815 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 10/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428011 |
| Principal investigator 1 | Novo Nordisk AS | $73.20 | 10/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811691107 |
| Principal investigator 1 | Novo Nordisk AS | $73.20 | 10/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811880371 |
| Principal investigator 1 | Novo Nordisk AS | $73.20 | 10/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811901303 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 10/26/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832623583 |
| Principal investigator 1 | PFIZER INC. | $3,145.23 | 10/26/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832706479 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 10/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811412995 |
| Principal investigator 1 | Novo Nordisk AS | $4,672.26 | 10/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537131 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 10/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603237 |
| Principal investigator 1 | Novo Nordisk AS | $5,507.24 | 10/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770431 |
| Principal investigator 1 | Novo Nordisk AS | $95.40 | 10/22/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650647 |
| Principal investigator 1 | Novo Nordisk AS | $95.40 | 10/22/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650653 |
| Principal investigator 1 | Novo Nordisk AS | $95.40 | 10/22/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894289 |
| Principal investigator 1 | Novo Nordisk AS | $95.40 | 10/22/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894291 |
| Principal investigator 1 | Novo Nordisk AS | $95.40 | 10/22/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894293 |
| Principal investigator 1 | PFIZER INC. | $8,820.00 | 10/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832517615 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 10/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832517625 |
| Principal investigator 1 | PFIZER INC. | $670.95 | 10/22/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832599637 |
| Principal investigator 1 | PFIZER INC. | $7,566.75 | 10/21/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 832616963 |
| Principal investigator 1 | PFIZER INC. | $37,906.50 | 10/21/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832775271 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428001 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735583 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735589 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735595 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735599 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735605 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735611 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735617 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735623 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735861 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735865 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811735871 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736313 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736319 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736325 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736331 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736337 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811736343 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811740249 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799977 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799979 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811799981 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800031 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800033 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800079 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800081 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800083 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811800085 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886293 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886295 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886297 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886299 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886301 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886483 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886485 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886487 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886489 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886491 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886537 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886539 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886541 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811886543 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905363 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905365 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905367 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905369 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905371 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905413 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905415 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905417 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905419 |
| Principal investigator 1 | Novo Nordisk AS | $21.64 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905421 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905465 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905467 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905469 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905471 |
| Principal investigator 1 | Novo Nordisk AS | $13.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9775-4708 | No dispute reported | 06/30/2026 | 811905473 |
| Principal investigator 1 | Novo Nordisk AS | $27.90 | 10/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811700185 |
| Principal investigator 1 | PFIZER INC. | $8,618.40 | 10/19/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832862092 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 10/18/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711569 |
| Principal investigator 1 | PFIZER INC. | $5,300.31 | 10/16/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832703433 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $89,936.39 | 10/15/2021 | Non-covered Recipient Entity PMG RESEARCH LLC | Not supplied | No dispute reported | 06/30/2026 | 809523339 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $46,129.49 | 10/15/2021 | Non-covered Recipient Entity PMG RESEARCH LLC | Not supplied | No dispute reported | 06/30/2026 | 809540319 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 10/15/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299271 |
| Principal investigator 1 | PFIZER INC. | $3,533.49 | 10/13/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832763739 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 10/13/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832894815 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,500.00 | 10/11/2021 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN | No dispute reported | 06/30/2026 | 860871397 |
| Principal investigator 1 | PFIZER INC. | $668.25 | 10/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600117 |
| Principal investigator 1 | PFIZER INC. | $17,982.92 | 10/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832749659 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721005 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721015 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721035 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721045 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721054 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721147 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721157 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721165 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721175 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810798989 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810798999 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799009 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799019 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799029 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799141 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799151 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810801877 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811321969 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811321977 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811321987 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322313 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322323 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322331 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322341 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322454 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322463 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325097 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811325107 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811331367 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469025 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469035 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469079 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469087 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469097 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469103 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469113 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469341 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469348 |
| Principal investigator 1 | Novo Nordisk AS | $28.45 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811480433 |
| Principal investigator 1 | Novo Nordisk AS | $2,500.00 | 10/08/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650659 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686835 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686841 |
| Principal investigator 1 | Novo Nordisk AS | $600.00 | 10/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687503 |
| Principal investigator 1 | Novo Nordisk AS | $609.00 | 10/08/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780883 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 10/08/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780885 |
| Principal investigator 1 | Novo Nordisk AS | $1,270.00 | 10/08/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871397 |
| Principal investigator 1 | Novo Nordisk AS | $250.00 | 10/08/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894297 |
| Principal investigator 1 | PFIZER INC. | $18,160.20 | 10/08/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 832616925 |
| Principal investigator 1 | PFIZER INC. | $8,005.50 | 10/08/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832617967 |
| Principal investigator 1 | Novo Nordisk AS | $49.12 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804981 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292679 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292689 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292759 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292769 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292777 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293425 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293435 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293443 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293453 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293459 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595217 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595227 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595237 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595247 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595263 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595957 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595967 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595977 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837237 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837251 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837253 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837255 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837319 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837321 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863013 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863015 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 10/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810713645 |
| Principal investigator 1 | Novo Nordisk AS | $1,650.00 | 10/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 833635521 |
| Principal investigator 1 | Novo Nordisk AS | $330.00 | 10/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 833635525 |
| Principal investigator 1 | PFIZER INC. | $6,889.77 | 10/05/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832774641 |
| Principal investigator 1 | PFIZER INC. | $5,172.12 | 10/05/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832917165 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650165 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650171 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650175 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650181 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650617 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650623 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650629 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650635 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650641 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650953 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652171 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652177 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652183 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652188 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652195 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652199 |
| Principal investigator 1 | Novo Nordisk AS | $14.63 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652549 |
| Principal investigator 1 | Novo Nordisk AS | $12.25 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652555 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780865 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780867 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780869 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780871 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780873 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780875 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780877 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780879 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780881 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780977 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780979 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780981 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781083 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781085 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781087 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781089 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781091 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781093 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781095 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781097 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781099 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781101 |
| Principal investigator 1 | Novo Nordisk AS | $2.85 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781103 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781113 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871379 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871381 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871383 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871385 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871387 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871389 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871391 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871393 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871459 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871461 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871463 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871465 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871467 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871469 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871471 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871473 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871475 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871477 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871479 |
| Principal investigator 1 | Novo Nordisk AS | $30.00 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871481 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871487 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871489 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894273 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894275 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894277 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894279 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894281 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894283 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894285 |
| Principal investigator 1 | Novo Nordisk AS | $3.25 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894287 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894343 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894345 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894347 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894349 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894351 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894353 |
| Principal investigator 1 | Novo Nordisk AS | $10.82 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894355 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894357 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894359 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 10/04/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894361 |
| Principal investigator 1 | Novo Nordisk AS | $4,950.00 | 10/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 833635519 |
| Principal investigator 1 | Novo Nordisk AS | $330.00 | 10/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 833635523 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023569 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023589 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023591 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $26.89 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023609 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $79.12 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023623 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $92.59 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023625 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $92.59 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023627 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023675 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023677 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023719 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023721 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023723 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023725 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023727 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023729 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023731 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023747 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023749 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023751 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023753 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.03 | 10/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023755 |
| Principal investigator 1 | PFIZER INC. | $24,057.00 | 10/01/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832695581 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 09/30/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781081 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 09/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829773 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 09/30/2021 | Non-covered Recipient Entity Accellacare US Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832738055 |
| Principal investigator 1 | Novo Nordisk AS | $1,123.07 | 09/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242065 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299251 |
| Principal investigator 1 | Novo Nordisk AS | $25.06 | 09/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413024 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $142.20 | 09/29/2021 | Covered Recipient Physician | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 793081709 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $1,908.67 | 09/27/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023795 |
| Principal investigator 1 | Novo Nordisk AS | $4,919.82 | 09/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789151 |
| Principal investigator 1 | Novo Nordisk AS | $3,912.17 | 09/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099075 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652153 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652159 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652165 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781001 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781003 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781005 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781079 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781109 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781111 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871453 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871455 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871457 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811877773 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894335 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894337 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894339 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894371 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894373 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 09/27/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894375 |
| Principal investigator 1 | PFIZER INC. | $12,012.10 | 09/25/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832778975 |
| Principal investigator 1 | Novo Nordisk AS | $10,035.69 | 09/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721025 |
| Principal investigator 1 | Novo Nordisk AS | $11,287.24 | 09/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804991 |
| Principal investigator 1 | Novo Nordisk AS | $663.12 | 09/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293773 |
| Principal investigator 1 | Novo Nordisk AS | $4,590.00 | 09/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465829 |
| Principal investigator 1 | Novo Nordisk AS | $5,891.82 | 09/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595293 |
| Principal investigator 1 | Novo Nordisk AS | $20.25 | 09/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829757 |
| Principal investigator 1 | PFIZER INC. | $1,154.25 | 09/22/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832604193 |
| Principal investigator 1 | PFIZER INC. | $8,000.00 | 09/22/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 832617559 |
| Principal investigator 1 | PFIZER INC. | $10,820.00 | 09/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 832617597 |
| Principal investigator 1 | PFIZER INC. | $8,147.24 | 09/21/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832715605 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711541 |
| Principal investigator 1 | PFIZER INC. | $920.00 | 09/20/2021 | Non-covered Recipient Entity ACCELLACARE | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832581327 |
| Principal investigator 1 | PFIZER INC. | $113.80 | 09/20/2021 | Non-covered Recipient Entity ACCELLACARE | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832581621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,420.83 | 09/20/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793110329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,349.88 | 09/20/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793110331 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/17/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711551 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/17/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299241 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292739 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292749 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595937 |
| Principal investigator 1 | Novo Nordisk AS | $27.90 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811691101 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837247 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837249 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837311 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863007 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863009 |
| Principal investigator 1 | Novo Nordisk AS | $320.00 | 09/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863011 |
| Principal investigator 1 | PFIZER INC. | $35,214.75 | 09/15/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832618577 |
| Principal investigator 1 | PFIZER INC. | $7,288.95 | 09/14/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832754053 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810791475 |
| Principal investigator 1 | Novo Nordisk AS | $30.00 | 09/10/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650941 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 09/10/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652147 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 09/10/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780973 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 09/10/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780975 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798803 |
| Principal investigator 1 | Novo Nordisk AS | $3.25 | 09/10/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871425 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 09/10/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894319 |
| Principal investigator 1 | Novo Nordisk AS | $1,980.00 | 09/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804961 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857819 |
| Principal investigator 1 | Novo Nordisk AS | $23.46 | 09/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810791465 |
| Principal investigator 1 | PFIZER INC. | $540.00 | 09/08/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600497 |
| Principal investigator 1 | PFIZER INC. | $23,492.14 | 09/08/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832778965 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686261 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686267 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686273 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686279 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686341 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686345 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686745 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686751 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686757 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686763 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686769 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686775 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686781 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686787 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686805 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687067 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687073 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687079 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687085 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687091 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687097 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687103 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687109 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687115 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687121 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687127 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687133 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687139 |
| Principal investigator 1 | Novo Nordisk AS | $25.98 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687145 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687151 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691819 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691825 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691831 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691837 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691843 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691849 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691855 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691861 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691867 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811691873 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693101 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693107 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693113 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693119 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693123 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693129 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693135 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693141 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693147 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693153 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693159 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693165 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693171 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693177 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693195 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693201 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693207 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693761 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693765 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693771 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693777 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693783 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693789 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693797 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693801 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693807 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693813 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693821 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693825 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693831 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693837 |
| Principal investigator 1 | Novo Nordisk AS | $7.70 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790093 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790095 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790097 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790099 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790101 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790103 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790105 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790107 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790109 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790199 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790201 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790203 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790205 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790207 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790209 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790211 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790213 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790215 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790217 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790219 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790221 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790237 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790255 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790257 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790369 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790371 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790373 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790375 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790377 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790379 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790381 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790383 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790387 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790389 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790391 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790393 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790395 |
| Principal investigator 1 | Novo Nordisk AS | $25.98 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811790397 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791725 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791727 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791729 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791733 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791735 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791737 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791739 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791775 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791777 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791779 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791781 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791783 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791785 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791787 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791789 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791791 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791793 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791795 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791797 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791799 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791801 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791803 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791847 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791849 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791851 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791853 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791855 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791857 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791859 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791861 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791863 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791865 |
| Principal investigator 1 | Novo Nordisk AS | $5.56 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791867 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791869 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791871 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791873 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791875 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791877 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791879 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879161 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879163 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879165 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879167 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879169 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879171 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879173 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879175 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879177 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879215 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879217 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879239 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879241 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879243 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879245 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879247 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879249 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879289 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879297 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879299 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879375 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879377 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879379 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879381 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879383 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879385 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879387 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879389 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879391 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879393 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879395 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879435 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879437 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879443 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879445 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879447 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879449 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879451 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879453 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879455 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879457 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879459 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811879461 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880581 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880583 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880585 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880587 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880589 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880591 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880593 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880595 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880597 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880599 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880601 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880603 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880639 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880641 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880643 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880645 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880647 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880649 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880651 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880653 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880655 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880657 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880659 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880661 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880663 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880665 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880667 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880669 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880673 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880675 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880711 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880713 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880715 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880717 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880719 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880721 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880723 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880725 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880727 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880729 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880731 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880733 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880735 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880737 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880739 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880741 |
| Principal investigator 1 | Novo Nordisk AS | $25.98 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880743 |
| Principal investigator 1 | Novo Nordisk AS | $25.98 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880745 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811881709 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900741 |
| Principal investigator 1 | Novo Nordisk AS | $4.16 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900743 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900745 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900747 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900749 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900751 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900753 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900755 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900757 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900759 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900761 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900763 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900765 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900767 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900799 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900801 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900803 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900805 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900807 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900809 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900811 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900813 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900815 |
| Principal investigator 1 | Novo Nordisk AS | $5.56 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900821 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900823 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900825 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900851 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900853 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900855 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900857 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900859 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900861 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900863 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900865 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900867 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900869 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900871 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900873 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900875 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900877 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900879 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900881 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900883 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900885 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900897 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900899 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900901 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900903 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900905 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900907 |
| Principal investigator 1 | Novo Nordisk AS | $30.90 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900909 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901385 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901387 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901389 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901391 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901393 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901395 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901397 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901399 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901401 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901403 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901405 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901407 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901409 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901411 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901415 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901417 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901419 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901421 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901423 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901425 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901427 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901429 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901431 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901433 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901435 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901437 |
| Principal investigator 1 | Novo Nordisk AS | $7.70 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901439 |
| Principal investigator 1 | Novo Nordisk AS | $27.96 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901441 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901443 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901445 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901447 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901449 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901451 |
| Principal investigator 1 | Novo Nordisk AS | $30.90 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901453 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 09/03/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901893 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,293.61 | 09/02/2021 | Non-covered Recipient Entity Valley Weight Loss Clinic | Ph IIb dose finding vs placebo in patients with Ob | No dispute reported | 06/30/2026 | 840492763 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413043 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829767 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023585 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023587 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023593 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023595 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $94.48 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023611 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $80.73 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023663 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023707 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023709 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023711 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023713 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023715 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023717 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023733 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023735 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023737 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023739 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023741 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023743 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.72 | 09/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023745 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/01/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810713635 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/01/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242045 |
| Principal investigator 1 | Novo Nordisk AS | $5.25 | 09/01/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894317 |
| Principal investigator 1 | PFIZER INC. | $4,200.00 | 09/01/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832616981 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 08/31/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099153 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 08/31/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894321 |
| Principal investigator 1 | PFIZER INC. | $6,468.25 | 08/31/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832774651 |
| Principal investigator 1 | Novo Nordisk AS | $17,471.21 | 08/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 811216705 |
| Principal investigator 1 | Novo Nordisk AS | $4,868.78 | 08/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811322447 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 08/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 811751027 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 08/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 811751033 |
| Principal investigator 1 | Novo Nordisk AS | $1,215.49 | 08/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687163 |
| Principal investigator 1 | Novo Nordisk AS | $1,215.49 | 08/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811901455 |
| Principal investigator 1 | PFIZER INC. | $58,364.55 | 08/27/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832618597 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $382.80 | 08/26/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830756043 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $2,124.14 | 08/26/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023793 |
| Principal investigator 1 | Novo Nordisk AS | $990.00 | 08/26/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650947 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $8.20 | 08/25/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830750871 |
| Principal investigator 1 | Novo Nordisk AS | $2,889.49 | 08/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711561 |
| Principal investigator 1 | Novo Nordisk AS | $11,953.43 | 08/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993055 |
| Principal investigator 1 | Novo Nordisk AS | $187.50 | 08/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811303087 |
| Principal investigator 1 | Novo Nordisk AS | $7,130.98 | 08/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595947 |
| Principal investigator 1 | Novo Nordisk AS | $6,004.96 | 08/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829775 |
| Principal investigator 1 | Novo Nordisk AS | $651.35 | 08/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833887 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857817 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292719 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292729 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595255 |
| Principal investigator 1 | Novo Nordisk AS | $180.64 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9932-4737 | No dispute reported | 06/30/2026 | 811791545 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837243 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837245 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863001 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863003 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 08/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863005 |
| Principal investigator 1 | PFIZER INC. | $1,722.60 | 08/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832599646 |
| Principal investigator 1 | PFIZER INC. | $5,936.37 | 08/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832704787 |
| Principal investigator 1 | PFIZER INC. | $373,581.45 | 08/21/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832617805 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428071 |
| Principal investigator 1 | Novo Nordisk AS | $180.64 | 08/17/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811687157 |
| Principal investigator 1 | Novo Nordisk AS | $180.64 | 08/17/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811791731 |
| Principal investigator 1 | Novo Nordisk AS | $8.25 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804931 |
| Principal investigator 1 | Novo Nordisk AS | $8.25 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804951 |
| Principal investigator 1 | Novo Nordisk AS | $83.65 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993027 |
| Principal investigator 1 | Novo Nordisk AS | $8.25 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679999 |
| Principal investigator 1 | Novo Nordisk AS | $8.25 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680005 |
| Principal investigator 1 | Novo Nordisk AS | $8.25 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680011 |
| Principal investigator 1 | Novo Nordisk AS | $83.65 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811699095 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29,179.48 | 08/16/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793108219 |
| Principal investigator 1 | PFIZER INC. | $1,655.32 | 08/14/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832778507 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/13/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789145 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/13/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242035 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711607 |
| Principal investigator 1 | PFIZER INC. | $917.00 | 08/11/2021 | Non-covered Recipient Entity ACCELLACARE | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832775885 |
| Recipient | PFIZER INC. | $3,200.00 | 08/10/2021 | Covered Recipient Physician | PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 832531879 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023571 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023597 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023599 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023679 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023681 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023683 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023685 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023687 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023689 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023691 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023693 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023695 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023697 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023699 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023701 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023703 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.58 | 08/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023705 |
| Principal investigator 1 | PFIZER INC. | $1,642.95 | 08/06/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600507 |
| Recipient | PFIZER INC. | $1,400.00 | 08/05/2021 | Covered Recipient Physician | PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 832531869 |
| Principal investigator 1 | PFIZER INC. | $276.23 | 08/03/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832695115 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 08/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099139 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $94.95 | 08/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023575 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $94.95 | 08/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023613 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $81.13 | 08/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023661 |
| Principal investigator 1 | Novo Nordisk AS | $15,527.20 | 08/01/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650671 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128661 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128675 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465733 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808691 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808693 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808695 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829771 |
| Principal investigator 1 | Novo Nordisk AS | $70.44 | 07/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842131 |
| Principal investigator 1 | Novo Nordisk AS | $29.00 | 07/30/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894341 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650139 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650145 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650151 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650157 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650677 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650683 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650689 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650695 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650701 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650707 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650713 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650719 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650937 |
| Principal investigator 1 | Novo Nordisk AS | $43.89 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650959 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650965 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650973 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650979 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650985 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650991 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811650997 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651003 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651009 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651015 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651021 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651025 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651031 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651037 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811651043 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652135 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652141 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652205 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652211 |
| Principal investigator 1 | Novo Nordisk AS | $90.00 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652219 |
| Principal investigator 1 | Novo Nordisk AS | $54.00 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652223 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652229 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811652235 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780821 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780823 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780861 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780863 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780889 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780891 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780893 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780895 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780969 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780971 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780983 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780985 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780987 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780989 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780991 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780993 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780995 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780997 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811780999 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781105 |
| Principal investigator 1 | Novo Nordisk AS | $13.50 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811781107 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871373 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871375 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871377 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871401 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871403 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871405 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871407 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871409 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871411 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871413 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871415 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871417 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871419 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871421 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871423 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871427 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871429 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871431 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871433 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871435 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871437 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871439 |
| Principal investigator 1 | Novo Nordisk AS | $13.50 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871441 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871443 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871445 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871447 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871449 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871451 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871483 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811871485 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811877775 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894267 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894269 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894271 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894299 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894301 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894303 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894305 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894307 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894309 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894311 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894313 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894315 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894323 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894325 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894327 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894329 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894331 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894333 |
| Principal investigator 1 | Novo Nordisk AS | $16.23 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894363 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894365 |
| Principal investigator 1 | Novo Nordisk AS | $17.07 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894367 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811894369 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 07/29/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811895017 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789135 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810791493 |
| Principal investigator 1 | Novo Nordisk AS | $2,259.52 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299261 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 811327587 |
| Principal investigator 1 | Novo Nordisk AS | $8,053.17 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469331 |
| Principal investigator 1 | Novo Nordisk AS | $4,415.16 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680023 |
| Principal investigator 1 | Novo Nordisk AS | $7,587.00 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808683 |
| Principal investigator 1 | Novo Nordisk AS | $3,015.70 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837313 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 07/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 811866499 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $1,964.42 | 07/27/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023791 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 07/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465723 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 07/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808677 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 07/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808679 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 07/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808681 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 07/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842111 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 07/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842113 |
| Principal investigator 1 | Novo Nordisk AS | $160.00 | 07/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842115 |
| Principal investigator 1 | Novo Nordisk AS | $13,729.48 | 07/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413051 |
| Principal investigator 1 | Novo Nordisk AS | $374.36 | 07/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857821 |
| Principal investigator 1 | PFIZER INC. | $8,561.07 | 07/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832904061 |
| Principal investigator 1 | PFIZER INC. | $13,130.78 | 07/22/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162B2 IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832617975 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/21/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789125 |
| Principal investigator 1 | PFIZER INC. | $243.00 | 07/21/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832599655 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299317 |
| Principal investigator 1 | Novo Nordisk AS | $1,320.00 | 07/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537121 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/20/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829765 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811303105 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $298,241.71 | 07/19/2021 | Non-covered Recipient Entity PMG RESEARCH | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 793106631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $41,804.36 | 07/15/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793106307 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,491.91 | 07/15/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793106309 |
| Principal investigator 1 | Novo Nordisk AS | $49,351.35 | 07/14/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 811635445 |
| Principal investigator 1 | Novo Nordisk AS | $2,310.00 | 07/14/2021 | Non-covered Recipient Entity ACCELACARE OF WILMINGTON, LLC | NN9838-4862 | No dispute reported | 06/30/2026 | 811895019 |
| Principal investigator 1 | PFIZER INC. | $2,070.18 | 07/14/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832784751 |
| Recipient | PFIZER INC. | $940.00 | 07/12/2021 | Covered Recipient Physician | PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 832532109 |
| Principal investigator 1 | Novo Nordisk AS | $46.12 | 07/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099125 |
| Principal investigator 1 | PFIZER INC. | $4,081.05 | 07/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600137 |
| Principal investigator 1 | PFIZER INC. | $10,500.00 | 07/09/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 832617093 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023799 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023801 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023803 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023805 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023807 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023809 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023811 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $34.76 | 07/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023813 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/07/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810791483 |
| Principal investigator 1 | Novo Nordisk AS | $24.56 | 07/07/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537101 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/07/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829763 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 07/07/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857815 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,706.34 | 07/02/2021 | Non-covered Recipient Entity PMG RESEARCH LLC | Not supplied | No dispute reported | 06/30/2026 | 809536625 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,000.00 | 07/02/2021 | Non-covered Recipient Entity PMG RESEARCH LLC | Not supplied | No dispute reported | 06/30/2026 | 809536637 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $81.05 | 07/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023603 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711589 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 06/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798807 |
| Principal investigator 1 | PFIZER INC. | $1,103.89 | 06/30/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832830543 |
| Principal investigator 1 | Eli Lilly and Company | $307,374.00 | 06/29/2021 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | No dispute reported | 06/30/2026 | 819464873 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $253,312.19 | 06/28/2021 | Non-covered Recipient Entity PMG Research Inc | Ph IIb dose finding vs placebo in patients with Ob | No dispute reported | 06/30/2026 | 840492569 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789105 |
| Principal investigator 1 | Novo Nordisk AS | $2,982.71 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789161 |
| Principal investigator 1 | Novo Nordisk AS | $9,047.56 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469407 |
| Principal investigator 1 | Novo Nordisk AS | $6,393.53 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537437 |
| Principal investigator 1 | Novo Nordisk AS | $374.36 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811544161 |
| Principal investigator 1 | Novo Nordisk AS | $5,668.59 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798809 |
| Principal investigator 1 | Novo Nordisk AS | $2,453.62 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808751 |
| Principal investigator 1 | Novo Nordisk AS | $5,952.38 | 06/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863155 |
| Principal investigator 1 | PFIZER INC. | $696.28 | 06/28/2021 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832730289 |
| Principal investigator 1 | PFIZER INC. | $2,668.95 | 06/26/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832617985 |
| Principal investigator 1 | Novo Nordisk AS | $2,934.31 | 06/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 811216725 |
| Principal investigator 1 | Novo Nordisk AS | $19.00 | 06/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808605 |
| Principal investigator 1 | Novo Nordisk AS | $394.00 | 06/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842055 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $2,590.89 | 06/24/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830756221 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $276.44 | 06/24/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023601 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,860.80 | 06/24/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 EX 14870 Ph III in SARS Cov 2 Preventi | No dispute reported | 06/30/2026 | 840494697 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,901.10 | 06/23/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809490311 |
| Principal investigator 1 | Novo Nordisk AS | $24.56 | 06/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680931 |
| Principal investigator 1 | PFIZER INC. | $26,832.60 | 06/23/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | No dispute reported | 06/30/2026 | 832617795 |
| Principal investigator 1 | PFIZER INC. | $44,770.18 | 06/23/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162B2 IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832618607 |
| Principal investigator 1 | PFIZER INC. | $1,154.28 | 06/23/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832764791 |
| Principal investigator 1 | PFIZER INC. | $2,727.66 | 06/23/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832884905 |
| Principal investigator 1 | Novo Nordisk AS | $24.56 | 06/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680937 |
| Principal investigator 1 | PFIZER INC. | $827.66 | 06/22/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832760589 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/21/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299291 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/18/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789095 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/18/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428031 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/17/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57,075.10 | 06/17/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793104365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $37,524.04 | 06/17/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793104367 |
| Principal investigator 1 | PFIZER INC. | $10,500.00 | 06/15/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162B2 IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832616971 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $31.82 | 06/14/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752987 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $16.20 | 06/14/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830754845 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $189.45 | 06/14/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755759 |
| Principal investigator 1 | Novo Nordisk AS | $394.00 | 06/14/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465561 |
| Principal investigator 1 | Novo Nordisk AS | $19.00 | 06/14/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808603 |
| Principal investigator 1 | PFIZER INC. | $2,230.90 | 06/12/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832872804 |
| Principal investigator 1 | Novo Nordisk AS | $14.82 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128503 |
| Principal investigator 1 | Novo Nordisk AS | $19.95 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128517 |
| Principal investigator 1 | Novo Nordisk AS | $3.25 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128531 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465371 |
| Principal investigator 1 | Novo Nordisk AS | $55.38 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465545 |
| Principal investigator 1 | Novo Nordisk AS | $2.34 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465555 |
| Principal investigator 1 | Novo Nordisk AS | $4.87 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808599 |
| Principal investigator 1 | Novo Nordisk AS | $20.00 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808601 |
| Principal investigator 1 | Novo Nordisk AS | $4.00 | 06/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842053 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $31.82 | 06/09/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752977 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $3.76 | 06/09/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753673 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789085 |
| Principal investigator 1 | PFIZER INC. | $2,205.55 | 06/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832784675 |
| Principal investigator 1 | PFIZER INC. | $3,655.22 | 06/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832817807 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $0.94 | 06/08/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830754903 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711597 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $357.67 | 06/06/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023617 |
| Principal investigator 1 | PFIZER INC. | $1,327.05 | 06/05/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832605789 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $4.35 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830751911 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $529.20 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752015 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $78.40 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752373 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $228.29 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752925 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $3,803.55 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753177 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $23.29 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753233 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $2.88 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753307 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $24.80 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830754053 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $201.18 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755057 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $171.73 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755163 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $0.69 | 06/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755667 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 06/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811443505 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $7.86 | 06/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830751571 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $80.87 | 06/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752583 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $315.44 | 06/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753481 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $756.79 | 06/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753789 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $0.78 | 06/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830754749 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $27.17 | 06/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755797 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $83.63 | 06/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023579 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 05/31/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829769 |
| Principal investigator 1 | PFIZER INC. | $4,519.65 | 05/29/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832720931 |
| Principal investigator 1 | Novo Nordisk AS | $4,968.78 | 05/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799249 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $80.35 | 05/26/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830756219 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $305.84 | 05/26/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023659 |
| Principal investigator 1 | Novo Nordisk AS | $2,046.09 | 05/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099191 |
| Principal investigator 1 | Novo Nordisk AS | $6,861.98 | 05/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293833 |
| Principal investigator 1 | Novo Nordisk AS | $3,986.74 | 05/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299367 |
| Principal investigator 1 | Novo Nordisk AS | $400.00 | 05/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 811327615 |
| Principal investigator 1 | Novo Nordisk AS | $374.36 | 05/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811544141 |
| Principal investigator 1 | Novo Nordisk AS | $10,907.19 | 05/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680949 |
| Principal investigator 1 | Novo Nordisk AS | $3,772.69 | 05/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 811809393 |
| Principal investigator 1 | PFIZER INC. | $54,268.65 | 05/25/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832617159 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127971 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127985 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127999 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128477 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128491 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128597 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128609 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128621 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128633 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128647 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811136861 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465351 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465361 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465667 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465677 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465687 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465697 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465707 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465717 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465753 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465763 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808589 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808591 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808593 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808595 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808597 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808671 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808673 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808675 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808689 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842041 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842043 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842045 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842047 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842049 |
| Principal investigator 1 | Novo Nordisk AS | $120.00 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842051 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842069 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842109 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842125 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842127 |
| Principal investigator 1 | Novo Nordisk AS | $1.12 | 05/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842129 |
| Principal investigator 1 | PFIZER INC. | $2,654.10 | 05/22/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832604965 |
| Principal investigator 1 | PFIZER INC. | $3,193.49 | 05/22/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832870795 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 05/21/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428061 |
| Principal investigator 1 | PFIZER INC. | $5,771.40 | 05/21/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832897195 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,837.03 | 05/21/2021 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 793102679 |
| Principal investigator 1 | Eli Lilly and Company | $13,024.24 | 05/18/2021 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | No dispute reported | 06/30/2026 | 819462983 |
| Principal investigator 1 | PFIZER INC. | $9,406.80 | 05/18/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | No dispute reported | 06/30/2026 | 832617759 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $3,803.55 | 05/17/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830751589 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $300.48 | 05/17/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753861 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $16.20 | 05/17/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830754767 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,367.05 | 05/17/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793102459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,407.09 | 05/17/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793102461 |
| Principal investigator 1 | PFIZER INC. | $9,601.88 | 05/15/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832810497 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 05/14/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811446975 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 05/14/2021 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832735671 |
| Principal investigator 1 | PFIZER INC. | $2,490.00 | 05/14/2021 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832812945 |
| Principal investigator 1 | PFIZER INC. | $130.00 | 05/14/2021 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832842801 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 05/14/2021 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832912823 |
| Principal investigator 1 | PFIZER INC. | $1,998.00 | 05/13/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600127 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 05/12/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810713655 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,300.00 | 05/12/2021 | Non-covered Recipient Entity Pmg Research,Inc DBA Pmg Research Of Charleston,LLC | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise | No dispute reported | 06/30/2026 | 838660877 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,500.00 | 05/12/2021 | Non-covered Recipient Entity Pmg Research,Inc DBA Pmg Research Of Charleston,LLC | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise | No dispute reported | 06/30/2026 | 838660879 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 05/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 811330293 |
| Principal investigator 1 | Novo Nordisk AS | $2,003.90 | 05/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 811866507 |
| Principal investigator 1 | Novo Nordisk AS | $750.00 | 05/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4506 | No dispute reported | 06/30/2026 | 811866509 |
| Principal investigator 1 | PFIZER INC. | $696.28 | 05/10/2021 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832760009 |
| Principal investigator 1 | PFIZER INC. | $18,268.20 | 05/08/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | No dispute reported | 06/30/2026 | 832617769 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $59.00 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830751701 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $660.00 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830751951 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $529.20 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752023 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $4.35 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752299 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $4.70 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752393 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $676.88 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752541 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $3,803.55 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752871 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $25.02 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752947 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $23.29 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753139 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $2.88 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753401 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $21.05 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753725 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $218.44 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830754129 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $24.80 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830754327 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $171.73 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755183 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $1,140.00 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755201 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $3,772.09 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755323 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $0.69 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755565 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $3,772.09 | 05/07/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830755821 |
| Principal investigator 1 | PFIZER INC. | $10,196.14 | 05/07/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832749539 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $176.61 | 05/05/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023615 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $306.00 | 05/05/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 EX14870 Ph II III SARS COV 2 Ambulato | No dispute reported | 06/30/2026 | 840490817 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 05/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810789115 |
| Principal investigator 1 | PFIZER INC. | $3,467.01 | 05/05/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832723833 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $82.21 | 05/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023797 |
| Principal investigator 1 | PFIZER INC. | $52,297.65 | 05/01/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | No dispute reported | 06/30/2026 | 832617587 |
| Principal investigator 1 | PFIZER INC. | $10,708.17 | 05/01/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832828467 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $56.02 | 04/30/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752431 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $421.44 | 04/30/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830752791 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $28.65 | 04/30/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830753245 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 04/30/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,454.84 | 04/29/2021 | Non-covered Recipient Entity PMG RESEARCH | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 793101781 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428041 |
| Principal investigator 1 | Boehringer Ingelheim Canada Ltd.Ltee | $1,015.79 | 04/27/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV | No dispute reported | 06/30/2026 | 830756217 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/27/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428051 |
| Principal investigator 1 | Novo Nordisk AS | $5,010.65 | 04/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721271 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413033 |
| Principal investigator 1 | PFIZER INC. | $696.28 | 04/26/2021 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832778731 |
| Principal investigator 1 | PFIZER INC. | $460.35 | 04/24/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | No dispute reported | 06/30/2026 | 832617149 |
| Principal investigator 1 | PFIZER INC. | $15,499.06 | 04/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832865389 |
| Principal investigator 1 | Novo Nordisk AS | $11,764.58 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 810968911 |
| Principal investigator 1 | Novo Nordisk AS | $2,480.69 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992471 |
| Principal investigator 1 | Novo Nordisk AS | $7,192.12 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413061 |
| Principal investigator 1 | Novo Nordisk AS | $3,938.65 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811428663 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811464319 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680943 |
| Principal investigator 1 | Novo Nordisk AS | $2,979.75 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811834327 |
| Principal investigator 1 | Novo Nordisk AS | $4,462.05 | 04/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837335 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292423 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292433 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292443 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292453 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292641 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292651 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292661 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292671 |
| Principal investigator 1 | Novo Nordisk AS | $240.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292699 |
| Principal investigator 1 | Novo Nordisk AS | $0.30 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292709 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293001 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293011 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293021 |
| Principal investigator 1 | Novo Nordisk AS | $33.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293029 |
| Principal investigator 1 | Novo Nordisk AS | $24.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293037 |
| Principal investigator 1 | Novo Nordisk AS | $394.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293047 |
| Principal investigator 1 | Novo Nordisk AS | $108.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293057 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293067 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293075 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293085 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293094 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293101 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293109 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293311 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293321 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293331 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293339 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293347 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293357 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293367 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293373 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293383 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293392 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293399 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293409 |
| Principal investigator 1 | Novo Nordisk AS | $240.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293419 |
| Principal investigator 1 | Novo Nordisk AS | $891.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537429 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595013 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595023 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595031 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595041 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595341 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595351 |
| Principal investigator 1 | Novo Nordisk AS | $162.90 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595361 |
| Principal investigator 1 | Novo Nordisk AS | $24.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595371 |
| Principal investigator 1 | Novo Nordisk AS | $24.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595381 |
| Principal investigator 1 | Novo Nordisk AS | $24.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595391 |
| Principal investigator 1 | Novo Nordisk AS | $24.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595400 |
| Principal investigator 1 | Novo Nordisk AS | $24.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595411 |
| Principal investigator 1 | Novo Nordisk AS | $19.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595421 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595429 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595437 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595447 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595457 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595467 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595477 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595487 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595497 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595533 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595543 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595553 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595899 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595908 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595917 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595927 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811603497 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837231 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837233 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837235 |
| Principal investigator 1 | Novo Nordisk AS | $240.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837239 |
| Principal investigator 1 | Novo Nordisk AS | $240.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837241 |
| Principal investigator 1 | Novo Nordisk AS | $4.53 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837265 |
| Principal investigator 1 | Novo Nordisk AS | $2.86 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837267 |
| Principal investigator 1 | Novo Nordisk AS | $24.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837269 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837271 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837273 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837275 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837277 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837287 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837289 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837291 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837293 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837295 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837297 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837299 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837301 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837303 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837305 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837307 |
| Principal investigator 1 | Novo Nordisk AS | $240.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837309 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862951 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862953 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862955 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862995 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862997 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862999 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863023 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863025 |
| Principal investigator 1 | Novo Nordisk AS | $594.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863027 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863029 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863079 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863081 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863083 |
| Principal investigator 1 | Novo Nordisk AS | $5.98 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863085 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863087 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863089 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863091 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863093 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863095 |
| Principal investigator 1 | Novo Nordisk AS | $14.97 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863097 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863099 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863101 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863103 |
| Principal investigator 1 | Novo Nordisk AS | $240.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863143 |
| Principal investigator 1 | Novo Nordisk AS | $240.00 | 04/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863145 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/21/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711531 |
| Principal investigator 1 | PFIZER INC. | $6,540.92 | 04/21/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832711077 |
| Principal investigator 1 | PFIZER INC. | $29,644.65 | 04/20/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832617785 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711521 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811303077 |
| Principal investigator 1 | Novo Nordisk AS | $46.12 | 04/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798761 |
| Principal investigator 1 | PFIZER INC. | $22,695.54 | 04/17/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832892049 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804865 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804885 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804895 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804905 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804915 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804921 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804941 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805097 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805107 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805117 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810811313 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992647 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992661 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992673 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992685 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992945 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992957 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992971 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992985 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992999 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993013 |
| Principal investigator 1 | Novo Nordisk AS | $4.53 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993041 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993443 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993456 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993469 |
| Principal investigator 1 | Novo Nordisk AS | $108.00 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811010543 |
| Principal investigator 1 | Novo Nordisk AS | $8.58 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537041 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537051 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537081 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537091 |
| Principal investigator 1 | Novo Nordisk AS | $59.85 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537111 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537389 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537399 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537409 |
| Principal investigator 1 | Novo Nordisk AS | $60.00 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537419 |
| Principal investigator 1 | Novo Nordisk AS | $488.70 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679959 |
| Principal investigator 1 | Novo Nordisk AS | $657.00 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679965 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679983 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679987 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679993 |
| Principal investigator 1 | Novo Nordisk AS | $4.50 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680017 |
| Principal investigator 1 | Novo Nordisk AS | $0.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680919 |
| Principal investigator 1 | Novo Nordisk AS | $13.25 | 04/16/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $53,083.49 | 04/15/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793100795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $581,273.05 | 04/15/2021 | Non-covered Recipient Entity PMG RESEARCH | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 793100799 |
| Principal investigator 1 | PFIZER INC. | $1,215.00 | 04/14/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600955 |
| Principal investigator 1 | PFIZER INC. | $10,500.00 | 04/10/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | No dispute reported | 06/30/2026 | 832623573 |
| Principal investigator 1 | PFIZER INC. | $37,280.14 | 04/10/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832811075 |
| Principal investigator 1 | PFIZER INC. | $1,871.10 | 04/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832604983 |
| Principal investigator 1 | PFIZER INC. | $1,731.42 | 04/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832784759 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/07/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811427991 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811427981 |
| Principal investigator 1 | Novo Nordisk AS | $6.26 | 04/06/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829753 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $172.87 | 04/04/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023657 |
| Principal investigator 1 | PFIZER INC. | $3,527.55 | 04/03/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832617995 |
| Principal investigator 1 | PFIZER INC. | $27,376.89 | 04/03/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832724511 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $80.16 | 04/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023671 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 04/01/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811427971 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 03/31/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099181 |
| Principal investigator 1 | Novo Nordisk AS | $20.25 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099035 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099049 |
| Principal investigator 1 | Novo Nordisk AS | $13.50 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099063 |
| Principal investigator 1 | Novo Nordisk AS | $4,833.72 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299357 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811303067 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811412985 |
| Principal investigator 1 | Novo Nordisk AS | $13.50 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798757 |
| Principal investigator 1 | Novo Nordisk AS | $54.00 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798759 |
| Principal investigator 1 | Novo Nordisk AS | $90.00 | 03/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829751 |
| Principal investigator 1 | PFIZER INC. | $79,957.80 | 03/27/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832617775 |
| Principal investigator 1 | PFIZER INC. | $31,778.75 | 03/27/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832699971 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $1,600.30 | 03/25/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 03/25/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793099525 |
| Principal investigator 1 | Novo Nordisk AS | $250.00 | 03/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721261 |
| Principal investigator 1 | Novo Nordisk AS | $1,930.29 | 03/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293793 |
| Principal investigator 1 | Novo Nordisk AS | $17,690.08 | 03/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469399 |
| Principal investigator 1 | Novo Nordisk AS | $14,190.65 | 03/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 811751039 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 03/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829747 |
| Principal investigator 1 | PFIZER INC. | $2,478.60 | 03/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600965 |
| Principal investigator 1 | PFIZER INC. | $31,747.95 | 03/24/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832617577 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711503 |
| Principal investigator 1 | PFIZER INC. | $40,838.70 | 03/20/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832843835 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711511 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292367 |
| Principal investigator 1 | Novo Nordisk AS | $878.40 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292377 |
| Principal investigator 1 | Novo Nordisk AS | $2.44 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292387 |
| Principal investigator 1 | Novo Nordisk AS | $22.00 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292397 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292403 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292413 |
| Principal investigator 1 | Novo Nordisk AS | $40.00 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292991 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293119 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293127 |
| Principal investigator 1 | Novo Nordisk AS | $5.72 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293137 |
| Principal investigator 1 | Novo Nordisk AS | $651.60 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811293145 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299231 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811594987 |
| Principal investigator 1 | Novo Nordisk AS | $3.02 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811594993 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595003 |
| Principal investigator 1 | Novo Nordisk AS | $72.00 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595303 |
| Principal investigator 1 | Novo Nordisk AS | $9.74 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595313 |
| Principal investigator 1 | Novo Nordisk AS | $0.30 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595323 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595331 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595503 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595513 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811595523 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837217 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837219 |
| Principal investigator 1 | Novo Nordisk AS | $1,485.00 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837221 |
| Principal investigator 1 | Novo Nordisk AS | $788.00 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837223 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837225 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837227 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837229 |
| Principal investigator 1 | Novo Nordisk AS | $8.00 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837261 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837263 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837279 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837281 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837283 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811837285 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862939 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862941 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862943 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862945 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862947 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811862949 |
| Principal investigator 1 | Novo Nordisk AS | $39.90 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863019 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863021 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863069 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863071 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863073 |
| Principal investigator 1 | Novo Nordisk AS | $2.65 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863075 |
| Principal investigator 1 | Novo Nordisk AS | $3.02 | 03/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811863077 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,372.95 | 03/18/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793099061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $335,674.11 | 03/18/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793099067 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $124,424.48 | 03/16/2021 | Non-covered Recipient Entity PMG Research Inc | Phase II study of BI456906 in Patients with T2DM O | No dispute reported | 06/30/2026 | 840492557 |
| Principal investigator 1 | PFIZER INC. | $696.28 | 03/16/2021 | Non-covered Recipient Entity PMG Research of WilmingtonLLC | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832843841 |
| Principal investigator 1 | Novo Nordisk AS | $180.64 | 03/15/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798755 |
| Principal investigator 1 | PFIZER INC. | $16,256.70 | 03/13/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832617957 |
| Principal investigator 1 | PFIZER INC. | $73,880.73 | 03/13/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832760311 |
| Principal investigator 1 | PFIZER INC. | $142,697.70 | 03/12/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832618569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68,699.19 | 03/12/2021 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 793098571 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127815 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127827 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127841 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127851 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127863 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127874 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127887 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127901 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127915 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811127929 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128569 |
| Principal investigator 1 | Novo Nordisk AS | $28.47 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811128583 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811464325 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811464335 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811464345 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811464355 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465195 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465205 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465215 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465225 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465235 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465245 |
| Principal investigator 1 | Novo Nordisk AS | $14.61 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465255 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465631 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465641 |
| Principal investigator 1 | Novo Nordisk AS | $44.46 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465651 |
| Principal investigator 1 | Novo Nordisk AS | $7.02 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465661 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811479027 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808373 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808375 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808377 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808379 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808381 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808383 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808385 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808387 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808389 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808391 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808393 |
| Principal investigator 1 | Novo Nordisk AS | $59.85 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808395 |
| Principal investigator 1 | Novo Nordisk AS | $60.00 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808397 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808399 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808661 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808663 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808665 |
| Principal investigator 1 | Novo Nordisk AS | $7.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808667 |
| Principal investigator 1 | Novo Nordisk AS | $166.14 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811808669 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842019 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842021 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842023 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842025 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842027 |
| Principal investigator 1 | Novo Nordisk AS | $4.99 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842029 |
| Principal investigator 1 | Novo Nordisk AS | $9.75 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842031 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842033 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842061 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842063 |
| Principal investigator 1 | Novo Nordisk AS | $7.50 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842065 |
| Principal investigator 1 | Novo Nordisk AS | $12.00 | 03/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811842067 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/10/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536935 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/09/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811427961 |
| Principal investigator 1 | Novo Nordisk AS | $2,784.34 | 03/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4481 | No dispute reported | 06/30/2026 | 811465773 |
| Principal investigator 1 | Novo Nordisk AS | $1,066.14 | 03/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811686847 |
| Principal investigator 1 | Novo Nordisk AS | $369.00 | 03/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811693183 |
| Principal investigator 1 | Novo Nordisk AS | $1,066.14 | 03/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811880781 |
| Principal investigator 1 | Novo Nordisk AS | $369.00 | 03/08/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4578 | No dispute reported | 06/30/2026 | 811900849 |
| Principal investigator 1 | PFIZER INC. | $1,819.80 | 03/06/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832600487 |
| Principal investigator 1 | PFIZER INC. | $456,814.97 | 03/06/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832721283 |
| Principal investigator 1 | Novo Nordisk AS | $70.86 | 03/05/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799123 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 03/05/2021 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 793097889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 03/05/2021 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 793097891 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/04/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810713625 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,031,652.24 | 03/04/2021 | Non-covered Recipient Entity PMG RESEARCH | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 793097825 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $177.65 | 03/03/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023665 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $960.40 | 03/03/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Ob | No dispute reported | 06/30/2026 | 840494695 |
| Principal investigator 1 | PFIZER INC. | $29,869.30 | 03/03/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | No dispute reported | 06/30/2026 | 832616955 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 03/02/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811833891 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $82.64 | 03/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023669 |
| Principal investigator 1 | PFIZER INC. | $2,612.38 | 02/27/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832718609 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 02/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099103 |
| Principal investigator 1 | Novo Nordisk AS | $200.00 | 02/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 811469389 |
| Principal investigator 1 | Novo Nordisk AS | $250.00 | 02/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811834323 |
| Principal investigator 1 | Novo Nordisk AS | $5.72 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992485 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811602733 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603095 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603103 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603113 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603123 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603131 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603141 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603151 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603161 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603171 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603180 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603189 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603199 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603209 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603219 |
| Principal investigator 1 | Novo Nordisk AS | $6.08 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811603227 |
| Principal investigator 1 | Novo Nordisk AS | $0.20 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679211 |
| Principal investigator 1 | Novo Nordisk AS | $325.80 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679217 |
| Principal investigator 1 | Novo Nordisk AS | $438.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679275 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770361 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770363 |
| Principal investigator 1 | Novo Nordisk AS | $3.20 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770365 |
| Principal investigator 1 | Novo Nordisk AS | $11.20 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770367 |
| Principal investigator 1 | Novo Nordisk AS | $39.90 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770369 |
| Principal investigator 1 | Novo Nordisk AS | $9.74 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770371 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770373 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770375 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770377 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770379 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770381 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770383 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770425 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770427 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811770429 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811857825 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867879 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867881 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867883 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867885 |
| Principal investigator 1 | Novo Nordisk AS | $0.64 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867887 |
| Principal investigator 1 | Novo Nordisk AS | $40.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867889 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867893 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867895 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867897 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867899 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867901 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867903 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867941 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811867943 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890879 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890881 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890883 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890885 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890887 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890889 |
| Principal investigator 1 | Novo Nordisk AS | $8.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890891 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890893 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890895 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890897 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890899 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890901 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811890903 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4479 | No dispute reported | 06/30/2026 | 811891019 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832689893 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832741061 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832760595 |
| Principal investigator 1 | PFIZER INC. | $23,500.00 | 02/25/2021 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832912381 |
| Principal investigator 1 | Novo Nordisk AS | $260.00 | 02/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711637 |
| Principal investigator 1 | Novo Nordisk AS | $7,811.83 | 02/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711645 |
| Principal investigator 1 | Novo Nordisk AS | $13,707.94 | 02/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 811216715 |
| Principal investigator 1 | Novo Nordisk AS | $871.33 | 02/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811246461 |
| Principal investigator 1 | Novo Nordisk AS | $3,585.06 | 02/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4477 | No dispute reported | 06/30/2026 | 811292357 |
| Principal investigator 1 | Novo Nordisk AS | $250.00 | 02/24/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811304369 |
| Principal investigator 1 | PFIZER INC. | $2,424.60 | 02/24/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832605395 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804739 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804749 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804759 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804769 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804779 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804789 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804799 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804806 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804817 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804825 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804837 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804847 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804855 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810804875 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805001 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805011 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805021 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805031 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805041 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805051 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805061 |
| Principal investigator 1 | Novo Nordisk AS | $72.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805067 |
| Principal investigator 1 | Novo Nordisk AS | $39.90 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805077 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810805087 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810811323 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810811331 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992499 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992511 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992523 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992537 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992551 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992565 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992579 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992593 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992607 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992621 |
| Principal investigator 1 | Novo Nordisk AS | $3.02 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810992635 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993069 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993083 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993097 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993111 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993126 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993139 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993153 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993167 |
| Principal investigator 1 | Novo Nordisk AS | $8.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993181 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 810993431 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536745 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536755 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536765 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536774 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536783 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536794 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536803 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536813 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536823 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811536833 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537013 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537021 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537031 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537061 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537071 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537151 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537161 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537169 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537177 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537361 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537369 |
| Principal investigator 1 | Novo Nordisk AS | $9.74 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811537379 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811565875 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679223 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679229 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679235 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679241 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679247 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679251 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679259 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679263 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679269 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679281 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679287 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679291 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679297 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679941 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679947 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679953 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679971 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811679977 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680029 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680035 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680041 |
| Principal investigator 1 | Novo Nordisk AS | $3.05 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680883 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680889 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680897 |
| Principal investigator 1 | Novo Nordisk AS | $3.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680902 |
| Principal investigator 1 | Novo Nordisk AS | $1.95 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680907 |
| Principal investigator 1 | Novo Nordisk AS | $40.00 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN1436-4478 | No dispute reported | 06/30/2026 | 811680913 |
| Principal investigator 1 | Novo Nordisk AS | $3,092.52 | 02/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810799241 |
| Principal investigator 1 | Novo Nordisk AS | $20.25 | 02/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811099021 |
| Principal investigator 1 | Novo Nordisk AS | $644.85 | 02/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 811327597 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 02/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811412965 |
| Principal investigator 1 | Novo Nordisk AS | $19.17 | 02/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811412975 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 02/22/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829749 |
| Principal investigator 1 | PFIZER INC. | $2,569.15 | 02/20/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832695709 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299221 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/19/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811536927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $48,428.03 | 02/18/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793096059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58,171.37 | 02/18/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793096081 |
| Principal investigator 1 | PFIZER INC. | $1,306.19 | 02/13/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832748283 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/12/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242091 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/12/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811427951 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 02/11/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 811299211 |
| Principal investigator 1 | PFIZER INC. | $2,166.20 | 02/06/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832759121 |
| Principal investigator 1 | PFIZER INC. | $4,849.20 | 02/05/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832604975 |
| Principal investigator 1 | PFIZER INC. | $4,244.40 | 02/05/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832775537 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 02/03/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809490309 |
| Principal investigator 1 | Boehringer Ingelheim France S.A.S. | $82.88 | 02/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Ph IIb dose finding vs placebo in patients with Obesity | No dispute reported | 06/30/2026 | 827023667 |
| Principal investigator 1 | PFIZER INC. | $1,306.19 | 01/30/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832877521 |
| Principal investigator 1 | Novo Nordisk AS | $70.00 | 01/29/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811798805 |
| Principal investigator 1 | Novo Nordisk AS | $3,540.65 | 01/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9536-4388 | No dispute reported | 06/30/2026 | 810721139 |
| Principal investigator 1 | Novo Nordisk AS | $11,372.12 | 01/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4576 | No dispute reported | 06/30/2026 | 810959971 |
| Principal investigator 1 | Novo Nordisk AS | $967.27 | 01/28/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9536-4373 | No dispute reported | 06/30/2026 | 811634687 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 01/27/2021 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 793092975 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 01/27/2021 | Non-covered Recipient Entity PMG RESEARCH INC | PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 793092977 |
| Principal investigator 1 | Eli Lilly and Company | $9,163.65 | 01/26/2021 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | No dispute reported | 06/30/2026 | 819466471 |
| Principal investigator 1 | Novo Nordisk AS | $381.19 | 01/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | EX9924-4473 | No dispute reported | 06/30/2026 | 810711493 |
| Principal investigator 1 | Novo Nordisk AS | $374.36 | 01/26/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9535-4321 | No dispute reported | 06/30/2026 | 811242081 |
| Principal investigator 1 | PFIZER INC. | $446.18 | 01/23/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832762423 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 01/21/2021 | Non-covered Recipient Entity PMG RESEARCH | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | No dispute reported | 06/30/2026 | 793092467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52,717.18 | 01/21/2021 | Non-covered Recipient Entity PMG RESEARCH | A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection | No dispute reported | 06/30/2026 | 793092469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40,921.97 | 01/18/2021 | Non-covered Recipient Entity PMG RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | No dispute reported | 06/30/2026 | 793092205 |
| Principal investigator 1 | PFIZER INC. | $604.80 | 01/16/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832605405 |
| Principal investigator 1 | PFIZER INC. | $661.50 | 01/16/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832688607 |
| Principal investigator 1 | PFIZER INC. | $3,713.85 | 01/16/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832807577 |
| Principal investigator 1 | PFIZER INC. | $1,306.19 | 01/16/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832850745 |
| Principal investigator 1 | Novo Nordisk AS | $25.00 | 01/15/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811413071 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 01/15/2021 | Non-covered Recipient Entity PMG RESEARCH, INC | NN9924-4635 | No dispute reported | 06/30/2026 | 811829759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $813.33 | 01/15/2021 | Non-covered Recipient Entity PMG RESEARCH INC | A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS | No dispute reported | 06/30/2026 | 793091893 |
| Principal investigator 1 | PFIZER INC. | $4,309.20 | 01/12/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE | No dispute reported | 06/30/2026 | 832604643 |
| Principal investigator 1 | PFIZER INC. | $8,599.50 | 01/12/2021 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832770527 |
| Principal investigator 1 | PFIZER INC. | $22,537.15 | 01/09/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 832714387 |
| Principal investigator 1 | PFIZER INC. | $2,612.38 | 01/08/2021 | Non-covered Recipient Entity PMG Research Inc | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832701339 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $10,500.00 | 01/04/2021 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON, LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older | No dispute reported | 06/30/2026 | 848738985 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,000.00 | 01/04/2021 | Non-covered Recipient Entity PMG RESEARCH OF WILMINGTON, LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older | No dispute reported | 06/30/2026 | 848760423 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,416.50 | 01/01/2021 | Non-covered Recipient Entity Pmg Research Of Wilmington | Phase II study of BI456906 in Patients with T2DM O | No dispute reported | 06/30/2026 | 840494783 |